PARP1 and cancer: The above studies show that inhibition of Wnt signaling in diverse Wnt/β‐catenin‐high cancers decreased the expression of HR and FA pathway genes, leading to a BRCA‐like state and acquisition of PARP inhibitor sensitivity in tumors.